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Abstract
Background: Acinetobacter baumannii is one of the main causes of morbidity and mortality in critical condition
patients. The pathogen’s ability to survive under a wide range of environment conditions and to persist for long periods
of time on areas represents a frequent cause of endemic infection hotbeds especially in the Intensive Care Unit.
The objectives of the study are: determining the 5-year incidence of A. baumannii infection in patients admitted in the
ICU which needed mechanical ventilation; the analysis of these cases regarding pathological antecedents; processing the
data regarding these cases; gradual analysis of the susceptibility/resistance of isolated A. baumannii strains; observing the
emergence of A. baumannii infection in patients transferred into the ICU.
Methods: We have performed an observational retrospective study regarding the incidence of Acinetobacter baumannii
infections in the Intensive Care Unit of the Hospital of Infectious Diseases and Pneumophtisiology “Victor
Babes” Timisoara, Clinic II Infectious Diseases, during June 2011 – June 2015.
Results: We have identified a high prevalence of Acinetobacter baumannii infection, with an average period of
6 days. Bronchial suction was the most common pathological product in the study (90 % of the cases). Resistance to
antimicrobials has been determined: the lowest resistance was recorded for ampicillin + sulbactam (81.1 %), and the
highest resistance rate was recorded for ceftazidime and imipenem (94.6 % each). When comparing resistance to third
generation cephalosporins, the difference was not statistically significant (94.6 % for ceftazidime vs. 86.5 % for
cefoperazone, p = 0.117). Within the present study we were able to observe a significantly high resistance of the
germ to carbapenems, with a good sensitivity to aminoglycosides, and to colistin. Only one strain of Acinetobacter
baumannii was resistant to all classes of tested antibiotics.
Conclusions: Generally, carbapenems represented the elective treatment in severe infections; however, the number of
carbapenem-resistant Acinetobacter baumannii strains is growing, dramatically reducing therapeutic options, fact that
brings back to our attention reusing colistin, although the administration of this antibiotic has been limited due to new
antibiotics classes.
Keywords: Acinetobacter baumannii, Intensive Care Unit, Mechanical ventilation, Antibiotic resistance, Infection
* Correspondence: marinescu_adelina24@yahoo.com
2Clinical Hospital for Infectious Diseases Dr. Victor Babes, Strada Gheorghe
Adam, Nr. 13, Timisoara, Romania
Full list of author information is available at the end of the article
© 2016 Lăzureanu et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lăzureanu et al. BMC Infectious Diseases 2016, 16(Suppl 1):95
DOI 10.1186/s12879-016-1399-0
Background
Acinetobacter baumannii is a feared Gram-negative bacil-
lus, non-fermentative, capsulated, aerobic, and ubiquitous,
which gains territory in the fight against nosocomial infec-
tions, especially in the ventilated patient. The emergence
and fast spread of this germ raises signs of difficulty as
regards the therapeutic management of critical patients.
This bacteria’s pan resistance, achieved through insuffi-
ciently elucidated mechanism, places Acinetobacter bau-
mannii on the list of potentially lethal pathogenic agents.
In Central Asia and Eastern Europe different levels of
resistance have been recorded; antimicrobial resistance
was reported as a serious threat in countries such as
Belarus, Serbia, Switzerland, the Former Yugoslav
Republic of Macedonia and Turkey. Switzerland and
northern European countries generally face low antibiotic
resistance and high awareness, but a recent report has
identifies relatively high resistance to carbapenems in Aci-
netobacter spp. [1].
Objectives: determining the 5-year incidence of A. bau-
mannii infection in patients admitted in the ICU which
needed mechanical ventilation; the analysis of these cases
regarding pathological antecedents; processing the data
regarding these cases, with several measures for limiting
the transmission of nosocomial infections, especially in
patients that require mechanical ventilation; gradual
analysis of the susceptibility/resistance of isolated A.
baumannii strains; observing the emergence of A. bau-
mannii infection in patients transferred into the ICU.
Methods
We have performed an observational retrospective study
regarding the incidence of Acinetobacter baumannii
infections in the Intensive Care Unit (ICU) of the Hospital
of Infectious Diseases and Pneumophtisiology “Dr. Victor
Babes” Timisoara, Clinic II Infectious Diseases, during
June 2011 – June 2015. The database has been processed
with Excel, Microsoft Office 2010 and SPSS Statistics for
Windows (version 22.0, IBM Corp, Armonk, NY, USA).
The whole database has been structurally built in Excel,
Microsoft Office 2010, using its statistic function. The
vertical histograms were used for comparisons and the
sectional graphics were used to report certain parts to a
whole. The emergence’s evolution was built using linear
graphics. The Z test was performed to ascertain differ-
ences between proportions. The statistical tests were
two-sided, and the value for statistical significance was
set at p ≤ 0.05.
All data come from patients admitted in the local ICU,
which is composed of 5 beds, 1 attending doctor, 5 assis-
tants and one nurse. Our ICU presents a low patient flow
which require, because of present or ulteriorly “gained”
pathologies, a longer hospitalization (with an average of
30 patients per year).
There were no specific criteria for including or excluding
the patients in the study, basically all mechanically venti-
lated patients with Acinetobacter baumannii infection were
included in the study.
All the patients transferred to the ICU required mech-
anical ventilation due to severe respiratory failure acquired
(patients known as bronchitic or asthmatic). Bronchial
suction was collected through regular methods by using
the sterile suction probe, in sterile recipients, by medical
assistants and the senior doctor. Hemocultures were proc-
essed in the Bactec system (Beckton-Dickinson, Franklin
Lakes, NJ, USA), the rest of the samples have been proc-
essed through conventional methods. Strain identification
was performed through classical bio-chemical methods
and through the Vitek 2 Compact system (BioMerieux,
Marcy-L'Étoile, France). Antibiotic testing was performed
through the Vitek 2 Compact system and also through the
Kirby-Bauer method, and results were interpreted ac-
cording to the guidelines elaborated by CLSI (Clinical
and Laboratory Standard Institute) [2].
Results and discussions
Between June 2011 and June 2015 we have investigated 37
patients admitted in the ICU coming from the 3 clinics
compiling the Hospital for Infectious Diseases "Dr. Victor
Babeș" Timișoara: Pneumology, Clinic I and Clinic II of
Infectious Diseases, respectively.
87 % of the patients presented chronic obstructive pul-
monary disease, the reason why various anterior antibiotic
regimens had been administered, like cephalosporins, ceph-
alosporins + quinolones, carbapenems, fact which could
represent an ulteriorly gained antibiotic resistance motif.
Only 13 % of the patients introduced in the study had not
received prior antibiotic treatment.
All patients within the present study had been trans-
ferred to the ICU from the very first hospitalization
hours because of the need for mechanical ventilation.
Bronchitic or asthmatiform pathology corroborated with
pancytopenic status; deterioration of the hemodynamic
status and of the respiratory parameters had imposed
this therapeutic behavior.
The bacterial strains had been isolated from the following
type of clinical samples: bronchial suctioning (33), hemo-
culture (1), venous catheter (2), urine (1) (Fig. 1).
The present signs and symptoms such as high fever,
aggravation of general condition, modification of bronchic
secretion, microbian flora encountered in the urine sum-
mary had determined a revision of the case towards other
diagnostic behaviors, with the request of additional inves-
tigations, adapted to each case. The catheter blood culture
was positive with a negative peripheral blood culture.
Prior to the admission into the ICU, the patient with posi-
tive hemoculture was bedsore, having been hospitalized
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multiple times, fact that could represent an access gate for
germs, especially the ubiquitous ones.
The timespan from admission to the ICU to A. bau-
mannii detection was, on average, 6 days. The average
hospitalization period of patients in the ICU was 28 days.
None of the patients had suffered surgical interventions
or invasive procedures prior to the admission in the
therapy section.
Data obtained after analyzing resistance to A. bau-
mannii strains isolated in the bacteriology lab showed
that this bacteria’s antibiotic resistance is high. Multi-
drug resistant bacteria are described as being resistant
to at least one agent in 3 or more antibiotic categories.
One of the possible causes of the Acinetobacter bau-
mannii resistance is non-judicious use of large
spectrum antibiotics.
In the past, the species of Acinetobacter showed
resistance only to penicillin G, today this resistance
is met only in “non-baumannii” species. Aminopeni-
cillin, aminopenicillin + clavulanic acid, 1st and 2nd
generation cephalosporins resistance defines the wild
phenotype [3]. Beta-lactam susceptibility in the
strains from our study is reproduced in Fig. 2. An
explanation to resistance growth can be provided by
the emergence of Acinetobacter strains producing
beta-lactamases.
Carbapenem resistance in A. baumannii has increas-
ingly been reported in European countries. The preva-
lence of carbapenem resistance appears to be highest in
Turkey, Greece, Italy, Spain, and England, and increas-
ing in Eastern Europe [4].
In our study, the lowest resistance was recorded for
ampicillin + sulbactam (81.1 %), and the highest resist-
ance rate was recorded for ceftazidime and imipenem
(94.6 % each). Resistance to third generation cephalospo-
rins such as ceftazidime was higher than that for fourth
generation cephalosporins such as cefepime (94.6 % vs.
89.2 %), p = 0.198 (Table 1). Conversely, resistance to
third generation cephalosporins such as cefoperazone
was lower than that for fourth generation cephalosporins
such as cefepime (86.5 % vs. 89.2 %), p = 0.359. When
comparing the two above mentioned third generation
cephalosporins, the difference was not statistically sig-
nificant (94.6 % for ceftazidime vs. 86.5 % for cefopera-
zone, p = 0.117). One of the explanations could be the
fact that generally ceftazidime is used more than cefo-
perazone in A. baumannii infections and this could
lead in time, alongside with other aspects, to the devel-
opment of resistance. The lack of statistical significance
is probably due on the one hand to the low number of
tested strains, and on the other hand to the overall
increased resistance to all tested antibiotics. Carbapen-
ems, particularly meropenem, represented the preferred
treatment in these severe infections; nevertheless, the
number of carbapenem-resistant Acinetobacter bau-
mannii strains is growing, fact that reduces dramatic-
ally the therapeutic options, particularly since it is well
known that Acinetobacter baumannii owns a gene class
Fig. 1 Clinical samples used for the isolation of Acinetobacter baumannii strains included in the study
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for beta-lactamases that can provide resistance to
carbapenems, the expression of these genes being con-
trolled by mobile promoters. There have also been dis-
covered other resistance genes, including class C
chromosomal beta-lactamase gene which provides re-
sistance to cephalosporins; these are controlled in the
same way [5].
Within the last 30 years, the use of colistin has been
limited due to toxicity issues, as compared to new
antibiotic classes. However, the use of colistin has
been revaluated in treating multidrug-resistant Acine-
tobacter baumannii strains, susceptible to colistin [6].
Retrospective studies and case reports support in spe-
cialty literature colistin treatment for patients with se-
vere central nervous system infection [7, 8]. The doses
need to be modified for patients with kidney failure.
Within the study we can observe a good susceptibility
of the to colistin as compared to the other tested antimi-
crobials – Fig. 3. The yearly susceptibility of Acinetobacter
baumannii to aminoglycosides and colistin shows the
metamorphosis power of the germ, while maintaining a
satisfying susceptibility to colistin – Fig. 4.
Fluoroquinolones resistance is given by the modifica-
tion of the targets; only 10 % of the tested strains in this
study proved susceptible to tested fluoroquinolones.
According to the antibiograms, the patients were
treated with colistin in 28 cases and in 9 cases other
therapeutic regimens were administered: penicillins
active on Gram-negative agents (piperacillin, ticarcillin),
cephalosporins (ceftazidime), associations of cephalosporins
with aminoglycosides or quinolones, and combinations of 2
antibiotics ticarcillin + tazobactam, ticarcillin + clavulanic
acid, ampicillin + sulbactam).
A single strains from our study developed pan resistance
(resistance to all the categories of tested antibiotics).
There is partial follow-up data available: 17 patients
died, but they were known with significant medical
history and multiple comorbidities such as acute myo-
cardial infarction, pulmonary thromboembolism, or
stroke. The other 20 patients were transferred back to
the previous wards (8 patients are still being followed
up within Pneumology clinics).
A limitation of this study can also be represented by the
impossibility of performing genetic tests to ascertain the
Table 1 Statistical analysis of resistance to antibiotics in the isolated strains of Acinetobacter baumannii
Antibiotic agent 1 Strains resistant to antibiotic 1, n/N (%) Antibiotic agent 2 Strains resistant to antibiotic 2, n/N (%) p value Z-score
imipenem 35/37 (94.6) meropenem 32/37 (86.5) 0.117 1.1917
ampicillin + sulbactam 30/37 (81.1) ticarcillin 32/37 (86.5) 0.264 −0.6308
ceftazidime 35/37 (94.6) cefoperazone 32/37 (86.5) 0.117 1.1917
ceftazidime 35/37 (94.6) cefepime 33/37 (89.2) 0.198 0.8518
cefoperazone 32/37 (86.5) cefepime 33/37 (89.2) 0.359 −0.3557
Fig. 2 Beta-lactam resistance of bacterial strains included in the study
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complex mechanisms of resistance to antibiotics, due
to technical reasons of equipment of the bacteriology
laboratory. The study will also have to be extended and
completed with other cases, being known the fact that
the higher the number of cases, the more complex and
useful the study is in elaborating concrete measures of
practical utility.
Conclusions
Acinetobacter baumannii remains one of the most
feared agents in nosocomial infections, due to its
ability to acquire quicker and tougher resistance
mechanisms as compared with other Gram-negative
bacteria. Our study has shown that a large number of
A. baumannii strains were resistant to the tested anti-
biotics. The lowest resistance was recorded for ampi-
cillin + sulbactam and the highest resistance rate was
recorded for ceftazidime and imipenem In these cases,
colistin may remain the only active antibiotic and it
becomes the preferred antibiotic in treating these
infections.
We consider that A. baumannii infection can be
considered a ubiquitous nosocomial infection with
long-term implications in poly-hospitalized patients.
Fig. 3 Aminoglycosides and colistin resistance of bacterial strains included in the study
Fig. 4 Yearly susceptibility to colistin of bacterial strains included in the study
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